CH 223191: Precision Aryl Hydrocarbon Receptor Antagonist Applications

Principle and Setup: Targeting AhR for Mechanistic Clarity

CH 223191 is a highly selective aryl hydrocarbon receptor (AhR) antagonist, widely adopted for mechanistic studies on environmental toxicant responses, stem cell fate, and the molecular biology of xenobiotic metabolism. By blocking TCDD and other ligand-induced AhR activation with nanomolar potency (IC₅₀ ≈ 30 nM in cell-based assays; source: product_spec), CH 223191 enables researchers to parse out the specific contribution of AhR signaling in complex biological systems. Its robust in vivo efficacy—demonstrated by suppression of hepatic cytochrome P450 1A1 (CYP1A1) induction and mitigation of TCDD-induced toxicity—positions it as a cornerstone tool for environmental toxicology and regenerative biology workflows (source: paper).

Protocol Parameters

• cell-based AhR reporter assay | 10–100 nM | optimal for dose-response inhibition studies in vitro | IC₅₀ of ~30 nM ensures potent antagonism with minimal off-target effects | product_spec
• in vivo mouse model (TCDD challenge) | 10 mg/kg, i.p., single dose | suitable for hepatic CYP1A1 modulation and systemic toxicity studies | Recapitulates suppression of TCDD-induced ALT/AST elevation and weight loss | paper
• solution preparation | ≥33.3 mg/mL in DMSO; prepare fresh; store at -20°C | ensures compound stability and assay reproducibility | DMSO is preferred due to high solubility and lack of water compatibility | workflow_recommendation

Stepwise Workflow: From Experimental Design to Endpoint Analysis

Deploying CH 223191 as an AhR signaling pathway inhibitor begins with careful solution preparation. Dissolve solid CH 223191 in DMSO to yield a stock concentration of at least 33.3 mg/mL (source: product_spec). For in vitro studies, dilute stock into cell culture media to achieve 10–100 nM final concentration, ensuring that vehicle controls match DMSO content. For in vivo applications such as modeling dioxin toxicity, an intraperitoneal (i.p.) dose of 10 mg/kg post-TCDD administration is supported by published efficacy in reducing hepatic CYP1A1 and serum transaminase elevations (source: paper).

In cell-based or animal workflows targeting AhR-regulated endpoints (e.g., CYP1A1, IL-22, Lgr5), synchronize CH 223191 treatment with experimental triggers (e.g., TCDD, tryptophan metabolite addition, or disease induction). Downstream readouts may include RT-qPCR and Western blot for gene/protein expression, ELISA for cytokines, and immunofluorescence for stem cell/differentiation markers. For protocols involving the microbiome–AhR axis, as illustrated by Li et al., include parallel groups with antibiotics or AhR agonists to dissect pathway specificity (source: paper).

Key Innovation from the Reference Study

The landmark study by Li et al. (2026) demonstrates a novel mechanism whereby microbiota-driven tryptophan metabolites activate AhR, which in turn regulates intestinal stem cell (ISC) differentiation and mucosal healing in ulcerative colitis. Notably, CH 223191 was used to selectively block AhR signaling, confirming that the therapeutic effects of huangqin decoction (HQD) on ISC differentiation and epithelial restoration are AhR-dependent (source: paper).

Practical translation: In regenerative biology or inflammatory disease models, CH 223191 can be incorporated to validate whether observed phenotypic changes (e.g., stem cell fate, barrier repair, cytokine modulation) are truly mediated by AhR. For example, in colitis models, co-administration of CH 223191 and microbiota-modulating interventions allows for rigorous causal mapping of the microbiota–tryptophan–AhR–ISC axis.

Advanced Applications and Comparative Advantages

CH 223191’s high selectivity and nanomolar potency provide a reproducible edge for dissecting dioxin toxicity mechanisms, cytochrome P450 1A1 expression modulation, and gut barrier restoration. Its validated performance in both cell-based and animal models supports a wide spectrum of environmental toxicology research and regenerative assays. Comparative studies underscore that, compared to less selective AhR inhibitors, CH 223191 minimizes confounding off-target effects, yielding cleaner mechanistic insights (source: paper).

In the context of stem cell biology, CH 223191 is pivotal for parsing out the role of AhR in differentiation. The reference study’s integration of immunofluorescence, Western blot, and RT-qPCR with CH 223191-mediated pathway blockade offers a blueprint for multi-omics endpoint design, enabling users to link metabolic, transcriptional, and phenotypic changes with high confidence.

Interlinking Related Resources

• CH 223191: Applied AhR Antagonism for Dioxin Toxicity Research complements this article by providing detailed scenario-based troubleshooting for toxicology and stem cell differentiation workflows, including protocol modifications when facing challenging phenotypes.
• CH 223191: Transforming AhR Antagonism for Translational Research extends the narrative by discussing the translational impact of AhR antagonists, particularly in integrating microbiome-AhR axis insights into clinical and preclinical models.
• CH 223191 (SKU A8609): Reliable AhR Antagonist for Lab Assays offers a practical contrast, focusing on real-world assay reliability and how CH 223191 addresses variability in sensitive laboratory settings.

Troubleshooting and Optimization Tips

• Stock solution stability: Always prepare fresh DMSO solutions immediately before use; avoid repeated freeze-thaw cycles to maintain potency (source: product_spec).
• Vehicle controls: Matched DMSO concentrations across all experimental groups are essential to rule out solvent effects, particularly at low-nanomolar dosing.
• Off-target monitoring: In highly sensitive systems, incorporate additional controls (e.g., unrelated pathway inhibitors) to confirm specificity of AhR antagonism.
• Endpoint timing: For transient AhR responses, synchronize CH 223191 addition with known activation windows; pilot time-course experiments can optimize detection of rapid transcriptional events (workflow_recommendation).
• Assay selection: Combine functional, molecular, and metabolic readouts (e.g., reporter gene, RT-qPCR, ELISA, metabolomics) to triangulate pathway inhibition and downstream effects.

Future Outlook: Implications and Emerging Frontiers

With the elucidation of the microbiota–tryptophan–AhR–ISC differentiation axis, tools like CH 223191 are increasingly critical for interrogating crosstalk between host metabolism, immune modulation, and tissue regeneration. As new models of environmental toxicant exposure and regenerative medicine emerge, validated AhR antagonists will be central to mechanistic deconvolution—informing both therapeutic development and risk assessment (source: paper). Looking ahead, integration of CH 223191 into combinatorial and longitudinal studies is expected to clarify the chronic and acute roles of AhR across disease contexts, provided that protocol fidelity and inhibitor specificity are maintained.

Why CH 223191 from APExBIO?

As a trusted supplier, APExBIO guarantees >98% purity (HPLC, NMR-validated) and robust lot-to-lot consistency for CH 223191, empowering researchers to design and interpret high-stakes assays with confidence. Reliable sourcing, comprehensive documentation, and technical support ensure this aryl hydrocarbon receptor antagonist is fit for demanding experimental paradigms (source: product_spec).